EGFR, KRAS and EML4-ALK. Predict eligibility for non-small cell lung cancer (NSCLC) targeted therapies with this. Help assess patients with NSCLC being considered for treatment with an EGFR TKI.
Monitor disease progression and therapy in individuals with small cell lung cancer (SCLC).
As the world’s leader in cancer diagnostics, we have extensive capabilities in molecular and genetic testing, including FISH (fluorescence in situ hybridization) testing for early detection of lung cancer.
Lung cancer is the leading cause of cancer-related deaths in the United States, and Non-small cell lung cancer (NSCLC) accounts for over 85% of all cases. Some NSCLC patients may benefit from targeted drug therapy based on specific genetic alterations in their tumors. Detection of ROS1 rearrangements in patients with NSCLC suggests eligibility for treatment with the tyrosine kinase inhibitor crizotinib.
For more details of ROS1 test, please see the test summary.
Dr. Aurelia Meloni-Ehrig, Chief Director, Cytogenetics, AmeriPath discusses the NSCLC-specific mutation panel and its potential benefits and compares and contrasts EML4-ALK mutation testing methodologies and communicates the advantages offered by FISH.
Dr. Dr. Govindan, Professor of Oncology, Washington University, shares Insights on Targeting Lung Cancer. How to harness to the potential of targeted therapy for lung cancer, the leading cause of cancer-related deaths.
See our guides for details on test selection, utilization, and interpretation. All information is based on peer-reviewed publications and practice guidelines.